Trial · NCT06052930
Immersive Virtual Reality for the Non-pharmacological Management of Parkinson's Disease
NCT06052930, Not applicable, Completed, Campus Neurológico Sénior
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Immersive Virtual Reality for the Non-pharmacological Management of Parkinson's Disease. Trials, record NCT06052930. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06052930
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Immersive Virtual Reality for the Non-pharmacological Management of Parkinson's Disease
- NCT number
- NCT06052930
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 30 participants, actual
- Lead sponsor
- Campus Neurológico Sénior
- Conditions
- Parkinson Disease
- Interventions
- HTC Vive™ Pro
- First posted
- 2023-09-25
- Last updated
- 2023-09-25
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline to 6-week in TUG cognitive test | 6 week | Change from baseline to 6-week in TUG cognitive test |
| Secondary | Change from baseline to each evaluation time point in TUG and TUG with motor and cognitive dual-tasking | 6, 12 and 16 weeks | Difference between groups in change from baseline to each evaluation time point in TUG and TUG with motor and cognitive dual-tasking |
| Secondary | Change from baseline to each evaluation time point in MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) | 6, 12 and 16 weeks | Difference between groups in change from baseline to each evaluation time point in MDS-UPDRS |
| Secondary | Change from baseline to each evaluation time point in mini-Balance Evaluation Systems Test (mini-BEST test) | 6, 12 and 16 weeks | Difference between groups in change from baseline to each evaluation time point in mini-BEST test |
| Secondary | Change from baseline to each evaluation time point in Montreal Cognitive Assessment (MoCA) | 6, 12 and 16 weeks | Difference between groups in change from baseline to each evaluation time point in MoCA |
| Secondary | Change from baseline to each evaluation time point in Stroop test | 6, 12 and 16 weeks | Difference between groups in change from baseline to each evaluation time point in Stroop test |
| Secondary | Change from baseline to each evaluation time point in Visual Object and Space Perception (VOSP) Battery (cube and fragmented letters) | 6, 12 and 16 weeks | Difference between groups in change from baseline to each evaluation time point in VOSP-cube analysis and VOSP-fragmented letters |
| Secondary | Change from baseline to each evaluation time point in Parkinson's Disease Questionnaire-39 items (PDQ-39) | 6, 12 and 16 weeks | Difference between groups in change from baseline to each evaluation time point in PDQ-39 score |
| Secondary | Change from baseline to each evaluation time point in Schwab and England (S&E) scale | 6, 12 and 16 weeks | Difference between groups in change from baseline to each evaluation time point in S\&E scale |
| Secondary | Change from baseline to each evaluation time point in Clinical and Patient Global Impression of severity | 6, 12 and 16 weeks | Difference between groups in change from baseline to each evaluation time point in Clinical and Patient Global Impression of severity |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Stroop Color-Word Test | Secondary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06052930
GET https://conductscience.org/api/trials/v1/NCT06052930/registered